Richard King
CIK 1013702 · Chief Executive Officer · last filed 2021-07-06
Richard King is a Chief Executive Officer who has filed 15 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for SPRB, was dated Jul 6, 2021. Across all open-market trades the lifetime net is −$47.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ADMS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1001 BRICKELL AVE 25TH FL
MIAMI, FL 33131
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SPRB | Chief Executive Officer | 30 | $40.34 | $1.2K | $0 | 2 | 2021-07-06 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Chief Operating Officer | 48,856 | $8.22 | $401.6K | -$63.7K | 4 | 2018-06-22 |
| TALPHERA, INC. (ACRX) Delisted | President and CEO | 6,728 | $0.86 | $5.8K | $16.0K | 6 | 2014-03-11 |
| TERCICA INC (TRCA) Delisted | President and C.O.O. | 22,000 | $7.87 | $173.1K | $0 | 2 | 2008-03-27 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-07-06 | SPRB | Other (J) | +2,230 | $21.2K | EDGAR |
| 2021-01-29 | SPRB | Grant (A) | — | $0 | EDGAR |
| 2018-06-22 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Sell (S) | −2,501 | -$63.7K | EDGAR |
| 2018-03-09 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +11,000 | $0 | EDGAR |
| 2018-03-01 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +10,000 | $250.7K | EDGAR |
| 2017-05-05 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +28,125 | $0 | EDGAR |
| 2014-03-11 | TALPHERA, INC. (ACRX) Delisted | Tax (F) | −11,599 | -$132.6K | EDGAR |
| 2014-02-06 | TALPHERA, INC. (ACRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-02-07 | TALPHERA, INC. (ACRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-02-13 | TALPHERA, INC. (ACRX) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).